[HTML][HTML] Targeting Tim-3 in cancer with resistance to PD-1/PD-L1 blockade
T Tian, Z Li - Frontiers in oncology, 2021 - frontiersin.org
Programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) blocking
therapy has completely changed the treatment pattern of malignant tumors. It has been …
therapy has completely changed the treatment pattern of malignant tumors. It has been …
[HTML][HTML] New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials
H Jin, S Qin, J He, J Xiao, Q Li, Y Mao… - International Journal of …, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most lethal tumors in China and worldwide,
although first-line therapies for HCC, such as atezolizumab and bevacizumab, have been …
although first-line therapies for HCC, such as atezolizumab and bevacizumab, have been …
[HTML][HTML] TIM-3 in leukemia; immune response and beyond
M Rezaei, J Tan, C Zeng, Y Li… - Frontiers in …, 2021 - frontiersin.org
T cell immunoglobulin and mucin domain 3 (TIM-3) expression on malignant cells has been
reported in some leukemias. In myelodysplastic syndrome (MDS), increased TIM-3 …
reported in some leukemias. In myelodysplastic syndrome (MDS), increased TIM-3 …
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
U Harkus, M Wankell, P Palamuthusingam… - Seminars in Cancer …, 2022 - Elsevier
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths in the
world, and for patients with advanced disease there are few therapeutic options available …
world, and for patients with advanced disease there are few therapeutic options available …
SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment
S Wang, R Wang, N Xu, X Wei, Y Yang, Z Lian… - Hepatology, 2023 - journals.lww.com
Conclusions: This study indicates that DOCK2 controls CD8+ T-cell infiltration in HCC, and
cholesterol sulfate synthesized by sulfotransferase 2B1 in tumor cells promotes effector T …
cholesterol sulfate synthesized by sulfotransferase 2B1 in tumor cells promotes effector T …
[HTML][HTML] The state of immunotherapy in hepatobiliary cancers
Hepatobiliary cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma
(CCA), and gallbladder carcinoma (GBC), are lethal cancers with limited therapeutic options …
(CCA), and gallbladder carcinoma (GBC), are lethal cancers with limited therapeutic options …
[HTML][HTML] TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression has been
a trending topic in recent years due to its differential expression in a wide range of …
a trending topic in recent years due to its differential expression in a wide range of …
[HTML][HTML] Novel immune checkpoints in esophageal cancer: from biomarkers to therapeutic targets
X Zhou, T Ren, H Zan, C Hua, X Guo - Frontiers in Immunology, 2022 - frontiersin.org
Esophageal cancer ranks as the sixth most common cause of cancer death worldwide. Due
to the limited efficacy of conventional therapeutic strategies, including surgery …
to the limited efficacy of conventional therapeutic strategies, including surgery …
Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
Despite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common
form of liver cancer, remains a major public health problem worldwide. The immune …
form of liver cancer, remains a major public health problem worldwide. The immune …
[HTML][HTML] TIM-3 and CEACAM1 are prognostic factors in head and neck squamous cell carcinoma
F Yang, Z Zeng, J Li, X Ren, F Wei - Frontiers in Molecular …, 2021 - frontiersin.org
Background: T-cell Immunoglobulin and Mucin domain-containing molecule-3 (TIM-3) is a
new immune checkpoint molecule which plays important and complex roles in regulating …
new immune checkpoint molecule which plays important and complex roles in regulating …